Relationship Between Pharmacokinetics and Safety of Vismodegib - OPTIVISMO-1

Locally Advanced Basal Cell Carcinoma Clinical Trial

— OPTIVISMO-1  

Official title:

Study of the Relationship Between the Pharmacokinetics of Vismodegib and Safety Data: a Pilot Study to Therapeutic Optimization in Patients With Basal Cell Carcinoma - OPTIVISMO-1

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03610022
• Other study ID #: CHUBX 2017/41
• Status: Completed
• Phase: Phase 4
• Start date: September 3, 2018
• Est. completion date: May 12, 2021

Study information

• Verified date: August 2022
• Source: University Hospital, Bordeaux
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Vismodegib (ERIVEDGE®) at the standard dose of 150 mg/day orally is indicated for the treatment of advanced Basal Cell Carcinoma (BCC) and is associated with many adverse effects. Cramps, alopecia, dysgeusia, weight loss and others observed in clinical practice, compromize compliance and often lead to treatment discontinuation. Currently, it is the only drug available in this indication. Our main objective is to assess the relationship between plasma concentrations of vismodegib, and the occurrence of adverse effects within 6 months of inclusion in the study.

Description:

In patients treated with the Hedgehog (Hh) signaling pathway inhibitor, vismodegib, for Basal Cell Carcinoma (BCC), intolerance to this drug is a cause of non-compliance to treatment and often requires therapy discontinuation in spite of its potent anticarcinomic action. Indeed, vismodegib, at the standard dose of 150 mg/day, leads to many heavy side effects often 1 month after therapy initiation. The major side effects are daily or multiple daily cramps (associated with hypometabolism) in 60% of patients, dysgeusia, ageusia and alopecia (related to stem cells), and tiredness. Currently, there is no recommendation for dose adjustment against the occurrence of these adverse effects, so that clinicians propose temporary or definitive therapeutic discontinuation for around 30% of patients. The management of these therapeutic pauses is a challenge for clinicians, as no data are available on their impact on treatment long-term response. We hypothesize that vismodegib side effects are related to high plasma concentrations of drug in many patients. To date, there is no data from phase 3 study, sparse pharmacokinetic data emanating from Phase 1 and 2 studies in various solid tumors.

Patients included are treated with vismodegib (Hedgehog (Hh) pathway inhibitor) for symptomatic metastatic BCC, or for advanced BCC when surgery and radiotherapy are not appropriate. Included patients are new patients initiating a treatment with vismodegib or patients already on vismodegib. The study of the relationship between plasma concentrations of vismodegib and tolerance, requires at each monthly follow-up visits, monitoring of: concentrations of free (unbound to the α1-GPA) and total (bound and unbound) forms of vismodegib, α1-GPA plasma concentrations, patient's status, data on safety and efficacy, and clinical and biological data (covariates that may modulate the vismodegib pharmacokinetics resulting in increased plasma concentrations). Patients will be followed for 6 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 27
• Est. completion date: May 12, 2021
• Est. primary completion date: May 12, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with BCC and annexial carcinoma histologically proven under treatment or new patients under vismodegib or patients who restarted treatment

• 18 years-old or older

• Complete medical record

• Members or beneficiaries of a social security system,

• Patients must have given informed consent, free and written.

Exclusion Criteria:

• Patients with or without BCC and not treated with vismodegib

• BCC patients who stopped treatment with vismodegib due to non-response or progression on treatment

• Patients under 18 years-old

• Patients whose medical record is incomplete

• Unaffiliated subjects or not beneficiaries of a security system social,

• Patients who have not been informed and have not given their consent, free and written,

• Pregnant and childbearing women without effective contraceptive method

• Patients with confusional state

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Basal Cell
• Locally Advanced Basal Cell Carcinoma
• Metastatic Basal Cell Carcinoma

Intervention

Drug:
• Treatment with vismodegib
Vismodegib 150 mg capsules is administered daily with or without food until disease progression or unacceptable toxicity. Patients are followed in the dermatologic unit of Bordeaux University Hospital (Saint André Hospital) every month. At each consultation, clinical and biological datas, and two blood samples are collected just before taking the drug. One sample is for vismodegib quantification (pharmacokinetic protocol), and the other for the determination of alpha-1 glycoprotein acid level

Locations

Country	Name	City	State
France	Chu de Bordeaux	Bordeaux

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Bordeaux

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Serious side effects (grade 2 or more) during the clinical response follow-up to vismodegib	Patients already on vismodegib will be monitored at inclusion and for 6 months (M0, M1, M2, M3, M4, M5). New patients will be monitored from the end of the first month after inclusion and during 6 months (M1, M2, M3, M4, M5, M6)	Occurrence from inclusion to 6 months visit
Secondary	Relationship between the plasma concentrations of free and/or total vismodegib, and covariates		From inclusion to 6 months visit
Secondary	Clinical response to vismodegib in term of efficacy	Classification into 4 categories: progression, stabilité, partial response and complete response according to RECIST criteria	at least at each visit, from inclusion to 6 months visit